15:11

How real-world studies complement randomized controlled trials | Jean-Pierre Riveline

07:12

Initiating GLP-1 receptor agonists: Managing side effects | Nicola Milne

08:47

SURMOUNT-1: Heralding a ‘golden age’ for obesity treatment | Louis Aronne

18:27

Ramadan fasting, feasts, and type 2 diabetes | Shehla Shaikh

22:15

Ramadan and type 1 diabetes: Supporting religious fasting | Simon Heller and Shehla Shaikh

02:56

Addressing the challenges of Ramadan for people with diabetes | Sanjay Kalra

02:58

Why type 2 diabetes is so challenging to manage in children | Phil Zeitler

02:04

Treatment priorities in children with type 2 diabetes | Julian Hamilton-Shield

02:15

When to screen for type 2 diabetes in children | AG Unnikrishnan

05:21

EMPULSE: The ‘missing link’ for empagliflozin in heart failure | Adriaan Voors

08:12

What is hypoglycemia-associated autonomic failure? | Sambit Das

09:35

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status | Mikhail Kosiborod

05:33

SAFES summit 2021: Using modern sulfonylureas | Mohammad Wali Naseri

38:55

Time to reconsider the person with shortness of breath: EMPEROR-Preserved

07:43

SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes | Stefano Del Prato

01:08

Time to reconsider the person with shortness of breath: EMPEROR-Preserved

04:04

The ADA/EASD type 1 diabetes consensus: Comprehensive and up to date | Parth Narendran

10:04

How will the TriMaster results impact patient-centered care? | Pinar Topsever

09:53

Management of type 1 diabetes: ADA/EASD consensus report | Anne Peters

04:12

The HARPdoc intervention for people with poor hypoglycemia awareness | Stephanie Amiel

07:40

The TriMaster study of individualized medicine in type 2 diabetes | Andrew Hattersley

07:22

FIGARO: Where will finerenone fit into diabetic kidney disease treatment | David Wheeler

18:00

DKD treatment update: SGLT2 inhibitors and finerenone | Ian de Boer & Amrit Lamba

08:27

EMPEROR-Preserved: Diabetes medication becomes first effective HFpEF therapy | Stefan Anker

04:43

EMPEROR-Preserved: The implications for primary care | Kevin Fernando

02:25

A Collaborative Community to address suicide risk in diabetes | Katharine Barnard-Kelly

15:34

An update on COVID-19 and diabetes | Stefan Bornstein

03:54

ADA 2021 – What do the GRADE results mean for clinical practice? | Patrick Holmes

03:58

ADA 2021 – The SURPASS trials so far: Tirzepatide, semaglutide, and type 2 diabetes | John Wilding

05:13

ADA 2021– SURPASS-5: Tirzepatide in people with insulin-dependent type 2 diabetes | Michelle Welch

05:22

ADA 2021 – GRADE: Head-to-head comparison of metformin add-ons for type 2 diabetes | Deborah Wexler

03:31

ADA 2021 – SUSTAIN-FORTE: Double the approved semaglutide dose in type 2 diabetes | Juan Pablo Frías

05:44

ADA 2021 – SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes | Juan Pablo Frías

06:00

ADA 2021 – SURPASS-3: Tirzepatide versus insulin degludec in type 2 diabetes | Francesco Giorgino

07:23

Suicide risk in diabetes: Why doctors may hesitate to screen, but shouldn't | Mary de Groot

25:36

The DiRECT approach to weight loss: Efficacious and pragmatic (with Alison Barnes)

22:47

Why psychosocial care matters: The psychological impact of hypoglycemia (with Christel Hendrieckx)

19:39

Why psychosocial care matters: The role of the PSAD (with Frank Snoek)

16:15

Why psychosocial care matters: Working with people using diabetes technology (with Thomas Kubiak)

15:49

Why psychosocial care matters: Diabetes distress (with William Polonsky)

24:51

Why psychosocial care matters: Optimal medication taking in diabetes (with Kirsty Winkley)

19:08

Why psychosocial care matters: Disengagement with diabetes (with Bill Polonsky)

19:03

Why psychosocial care matters: Supporting people with diabetes in the pandemic (with Michael Vallis)

06:00

STEP 4: Long-term semaglutide treatment combats weight regain | Domenica Rubino

08:07

STEP 2: A higher semaglutide dose in people with type 2 diabetes | Ildiko Lingvay

07:41

STEP 3: Semaglutide plus intensive lifestyle therapy for weight loss | Thomas A. Wadden

05:43

STEP 1: Semaglutide for weight loss | John Wilding

06:11

DAPA-CKD: Does confirmed renoprotection make the case for first-line SGLT2 inhibition? | Luigi Gnudi

05:09

EMPEROR-Reduced: Time for a change in the HF guidelines? | Miles Fisher

08:14

DAPA-CKD: Renal benefits of SGLT2 inhibition in people with and without diabetes | Hiddo Heerspink

06:28

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes | Milton Packer

11:41

The LIBERATES trial: Flash glucose monitoring in people with type 2 diabetes | Ramzi Ajjan

07:10

COVID-19 and diabetes: The current evidence | Juliana Chan

02:00

Type 2 diabetes and psychosocial care | Chantal Mathieu

03:45

Pediatric diabetes and psychosocial care | David Maahs

10:25

Type 1 diabetes and psychosocial care | Irl Hirsch

10:11

Expert commentary: The VERTIS-CV trial | Francesco Giorgino

07:17

Researcher comment: The VERTIS-CV trial | Chris Cannon

13:08

Researcher comment: Putting telehealth into practice for type 2 diabetes | Matthew Crowley

03:40

Expert commentary: Icosapent ethyl lowers cardiovascular risk in people with diabetes | Jay Shubrook